AAV5 RPGR Gene Therapy Vector Listed

Summary#

Order 2023-112-08-01 Amending the Domestic Substances List adds one living organism to the federal inventory of substances. The organism is the Recombinant and non-replicating adeno-associated virus serotype 5 (AAV5) vector expressing a retinitis pigmentosa GTPase regulator gene RPGR (AAV5-hRKp.RPGR), and the change took effect when the order was registered on July 21, 2023. Practically, that organism is no longer treated as a “new” substance under the federal new-substances rules.

What it does#

• Adds the named organism to Part 5 of the Domestic Substances List (the list of inanimate biotechnology products and living organisms).
• Removes the organism from the requirement to follow the New Substances Notification Regulations (Organisms) for future manufacture or import, because it has already been assessed and met the criteria for listing.
• The order was made under the Canadian Environmental Protection Act, 1999 and came into force on its registration date (July 21, 2023).
• The government notes this is an administrative action. It does not mean the government is endorsing the organism, nor does it exempt it from any other laws or regulations that might apply.

Who's affected#

• Organizations that make, import, sell or work with this specific AAV5 vector are the most directly affected. That includes biotech companies, research labs, and suppliers who already handled or plan to handle it.
• Regulators and health authorities involved in biological products and biosafety will notice the listing because it changes the substance’s regulatory status under the new-substances rules.
• It is unclear from the order whether any specific commercial products, clinical trials, patients, or named companies are affected.

Why it matters#

• Being on the Domestic Substances List means the organism is no longer subject to the extra notification and assessment steps that apply to new organisms. That can make it easier for businesses and researchers already using or importing it to proceed without repeating those notifications.
• The change is administrative and was done because the ministers were satisfied the organism had already been manufactured or imported and the assessment period had ended. The listing does not by itself indicate safety, approval for medical use, or exemption from other rules (for example, biosafety, clinical trial, or health-product regulations).